Lunit has inked a partnership with the Society for Immunotherapy of Cancer (SITC) to develop a research program that will include advanced AI.
The program will give SITC members access to Lunit SCOPE IO, which will allow them to conduct analyses of histologic features from hematoxylin and eosin whole slide images, including identification of tumor-infiltrating lymphocytes, macrophages, and endothelial cells; tissue segmentation; and quantitative immune phenotyping, the company said.
SITC members must apply to the program, and the application period is from February 1 to April 30. Application review will take two to three months, according to Lunit. Interested applicants may contact Siraj Ali, MD, PhD.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
